Development and characterization of clinical-grade 89Zr-trastuzumab for HER2/neu immunoPET imaging.
about
VEGF pathway targeting agents, vessel normalization and tumor drug uptake: from bench to bedsideMolecular Imaging of Biomarkers in Breast CancerMapping biological behaviors by application of longer-lived positron emitting radionuclidesTissue distribution studies of protein therapeutics using molecular probes: molecular imagingUpdate on time-of-flight PET imagingRole of positron emission tomography for the monitoring of response to therapy in breast cancerMechanistic and quantitative insight into cell surface targeted molecular imaging agent design.Non-invasive in vivo imaging of near infrared-labeled transferrin in breast cancer cells and tumors using fluorescence lifetime FRET.Antibody-based imaging of HER-2: moving into the clinic.Cerenkov luminescence imaging of medical isotopes.Development of a novel long-lived immunoPET tracer for monitoring lymphoma therapy in a humanized transgenic mouse model.Measuring the pharmacodynamic effects of a novel Hsp90 inhibitor on HER2/neu expression in mice using Zr-DFO-trastuzumabNon invasive imaging assessment of the biodistribution of GSK2849330, an ADCC and CDC optimized anti HER3 mAb, and its role in tumor macrophage recruitment in human tumor-bearing mice.Targeting HER2: a report on the in vitro and in vivo pre-clinical data supporting trastuzumab as a radioimmunoconjugate for clinical trials.Alternative chelator for ⁸⁹Zr radiopharmaceuticals: radiolabeling and evaluation of 3,4,3-(LI-1,2-HOPO).89Zr-Onartuzumab PET imaging of c-MET receptor dynamics.Detection of Cancer Metastases with a Dual-labeled Near-Infrared/Positron Emission Tomography Imaging AgentImmunoPET and biodistribution with human epidermal growth factor receptor 3 targeting antibody ⁸⁹Zr-RG7116In vivo targeting of HER2-positive tumor using 2-helix affibody molecules.Development, optimization, and validation of novel anti-TEM1/CD248 affinity agent for optical imaging in cancer89Zr-DFO-J591 for immunoPET of prostate-specific membrane antigen expression in vivo.Glypican-3-targeting F(ab')2 for 89Zr PET of hepatocellular carcinoma.D-Amino acid peptide residualizing agents bearing N-hydroxysuccinimido- and maleimido-functional groups and their application for trastuzumab radioiodinationInnovative proteomics for the discovery of systemically accessible cancer biomarkers suitable for imaging and targeted therapiesIntraoperative imaging of positron emission tomographic radiotracers using Cerenkov luminescence emissions.Imaging the L-type amino acid transporter-1 (LAT1) with Zr-89 immunoPETDevelopment of the designed ankyrin repeat protein (DARPin) G3 for HER2 molecular imaging.Challenges in nuclear medicine: innovative theranostic tools for personalized medicineCancer stratification by molecular imaging.Modular strategy for the construction of radiometalated antibodies for positron emission tomography based on inverse electron demand Diels-Alder click chemistry.Novel (89)Zr cell labeling approach for PET-based cell trafficking studiesThe next generation of positron emission tomography radiopharmaceuticals in oncology.Therapeutic approaches for HER2-positive brain metastases: circumventing the blood-brain barrier.Recent trends in antibody-based oncologic imagingPre-Clinical Assessment of Lu-Labeled Trastuzumab Targeting HER2 for Treatment and Management of Cancer Patients with Disseminated Intraperitoneal DiseaseA comparison of 111In- or 64Cu-DOTA-trastuzumab Fab fragments for imaging subcutaneous HER2-positive tumor xenografts in athymic mice using microSPECT/CT or microPET/CT.In vivo biodistribution and accumulation of 89Zr in mice.Molecular imaging of HER2-positive breast cancer: a step toward an individualized 'image and treat' strategy.Development of Lu-177-trastuzumab for radioimmunotherapy of HER2 expressing breast cancer and its feasibility assessment in breast cancer patients.Advances in immuno-positron emission tomography: antibodies for molecular imaging in oncology
P2860
Q26770678-2DEEF930-5496-4592-9D9E-49334AFBEBFCQ26772870-A10493E4-56A3-4072-8028-70798C2C0FF4Q26824070-D39BB961-0BEB-4E72-934C-3F5AA6BDD243Q26865516-C5684473-4156-4DB8-96A6-588DD8584280Q26992166-EFB08FC4-B71D-40E4-B04C-969A6E7DDA63Q28080621-E4BBCC06-E43D-4063-96E0-225F71E50198Q30383551-508A9BDE-79AA-4ECE-AE69-403414D72CA3Q30416226-4F47BA3A-79C4-408E-A62E-766546348D86Q30423880-7FA7D92D-E517-4349-AF39-C5365CED4047Q30499280-1C0A7AB3-118F-4E87-9A3A-8A47A111DD22Q30525314-4B6DE0B2-0503-41C6-9B51-DA6CA1E572E6Q33527397-F38290DF-8D89-4D4E-BA05-45067BB1B112Q33610361-F6E366B5-028F-4128-9CEF-3C1597E9AEB3Q33661325-CAAF6CB3-9894-4785-9905-47CD2B600035Q33761754-CCAB0FD4-0C1E-4244-9B4B-77AC8D7B4B95Q33841490-C11A3475-EC10-4EFB-83DF-B1EA8EFC7986Q34111208-9B4CFACC-23CD-4930-8363-2B31011B7AD5Q34223890-88004D12-117D-4BB7-A321-334AABD38699Q34231627-56B53104-9A96-469B-8FF7-5D77380EEC3FQ34334475-34D012C3-62A8-4F37-8016-996A20352A53Q34389457-67C82139-00AC-45D5-809B-D4DA123F40F1Q34657257-380BE908-508B-4A1E-A3A5-BBEBF2E8C0B5Q34718122-79F05C7E-36ED-47AA-842B-947F5D47D9B4Q34756337-094F12E1-2E53-449F-9562-382563A45AC4Q34876852-210CAD66-B3D5-485A-A3BB-22D81383AC35Q35021768-719CF486-052B-4537-BFFF-B74D3BF9E9C1Q35043734-21D4DDE4-91C8-4E97-8C44-855A9AA20191Q35104505-1D04AAF0-A1E1-47BA-99F2-63DAA0ED5CE0Q35380664-164A44A8-02A4-4CDA-ACDE-AE2592F2231DQ35394166-CE0DDDAE-210C-4F82-9279-B556EE55880AQ35462110-8A6BBD04-D84C-472A-9C0F-48FB3847ED61Q35525690-8A9946BA-C0C0-428F-B3EA-D57910A6C627Q35608531-DC82A728-EF1A-467B-B91A-B0F483E1DB3BQ35643425-04B557D2-12C9-494D-81A5-572E8417044EQ35650273-3C5CFF71-F1B9-43EF-BDC5-85B2F7E755A1Q35650526-7B14D1FD-A1BA-4B45-AC72-5A61B491A05DQ35923622-4AE85D54-AAD5-4D3B-AC4F-5C3D61CBBE6EQ36105964-AEE873CE-562E-4D24-B335-DA5ABA7202EEQ36182596-C175AB39-D1DD-451F-86FE-AF480F994F8CQ36339722-12EC404C-6C71-4EB5-BD31-F6C7F27545F5
P2860
Development and characterization of clinical-grade 89Zr-trastuzumab for HER2/neu immunoPET imaging.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh
2009年學術文章
@zh-hant
name
Development and characterizati ...... or HER2/neu immunoPET imaging.
@en
Development and characterizati ...... or HER2/neu immunoPET imaging.
@nl
type
label
Development and characterizati ...... or HER2/neu immunoPET imaging.
@en
Development and characterizati ...... or HER2/neu immunoPET imaging.
@nl
prefLabel
Development and characterizati ...... or HER2/neu immunoPET imaging.
@en
Development and characterizati ...... or HER2/neu immunoPET imaging.
@nl
P2093
P1476
Development and characterizati ...... or HER2/neu immunoPET imaging.
@en
P2093
Anna P Rademaker
Eli C F Dijkers
Elisabeth G E de Vries
Guus A M S van Dongen
Johan R de Jong
Jos G W Kosterink
Lars R Perk
Marjolijn N Lub-de Hooge
P304
P356
10.2967/JNUMED.108.060392
P407
P50
P577
2009-05-14T00:00:00Z